| Gene symbol | MLANA | Synonyms | MART-1, MART1 | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9p24.1 | dbXrefs | |
| Description | melan-A | ||||
| GTO ID | GTC0053 |
| Trial ID | NCT00612222 |
| Disease | Metastatic Melanoma | Skin Cancer |
| Altered gene | MART-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | MAGE-A1 F5 TCR-T cells |
| Co-treatment | ALVAC gp100 Vaccine |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization |
| Year | 2008 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 080056|08-C-0056 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||||
|
|||||||||||||||